Current Report Filing (8-k)
May 16 2019 - 4:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 16, 2019
MannKind Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50865
|
|
13-3607736
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
30930 Russell Ranch Road, Suite 300
Westlake Village, CA
|
|
91362
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(818) 661-5000
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the
Form 8-K
is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. of Form
8-K):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
MNKD
|
|
The Nasdaq Stock Market LLC
|
On May 16, 2019, MannKind Corporation (MannKind) issued a press release announcing MannKinds entry into an exclusive marketing and
distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. (AMSL Diabetes) for the commercialization of Afrezza
®
(insulin human)
Inhalation Powder in Australia. Under the terms of the agreement, AMSL Diabetes is responsible for obtaining regulatory and reimbursement approvals to distribute Afrezza in Australia. AMSL Diabetes is also responsible for sales, marketing, and
customer support and distribution activities. MannKind is responsible for the supply and manufacturing of Afrezza.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MANNKIND CORPORATION
|
|
|
|
|
Dated: May 16, 2019
|
|
|
|
By:
|
|
/s/ David Thomson, Ph.D., J.D.
|
|
|
|
|
|
|
David Thomson, Ph.D., J.D.
Corporate Vice
President, General Counsel and Secretary
|
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024